[ Search Options ]

Francisco Xavier Castellanos, M.D.

Name, Degree: F. Xavier Castellanos, M.D.
Role(s) in Work Group: Chair, ADHD and Disruptive Behavior Disorders Work Group
Institutional Affiliation(s): NYU School of Medicine; Nathan Kline Institute for Psychiatric Research
City, State: New York, NY; Orangeburg, NY

Biographical Sketch:

F. Xavier Castellanos, M.D., obtained his undergraduate degree in Linguistics at Vassar College, received a Master’s of Science in Experimental Psychology at the University of New Orleans, and his M.D. from Louisiana State University Medical Center in Shreveport. He completed a combined residency in Pediatrics, General Psychiatry, and Child and Adolescent Psychiatry at the University of Kentucky, and a research fellowship on the neurobiology of Attention-Deficit/Hyperactivity Disorder (ADHD) at the National Institute of Mental Health (NIMH) before becoming Chief of the NIMH ADHD Research Unit. In 2001, he established the Institute for Pediatric Neuroscience at the NYU School of Medicine Child Study Center, where he is the Brooke and Daniel Neidich Professor of Child and Adolescent Psychiatry, Professor of Radiology, Director of Research, and Senior Research Psychiatrist at the Nathan Kline Institute for Psychiatric Research. Dr. Castellanos chairs the ADHD and Disruptive Behavior Disorders Workgroup on the DSM-V Task Force and serves on the National Advisory Council on Drug Abuse for the National Institutes of Health. He has received many honors including the Blanche F. Ittleson Award from the American Psychiatric Association for his work on the neuroanatomy of ADHD. His work focuses on elucidating the neuroscience of ADHD through functional and structural brain imaging studies. His research is supported by NARSAD, the National Institute of Mental Health, the National Institute on Drug Abuse, and the Stavros S. Niarchos Foundation.

Uncompensated Affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V : calendar years 2005, 2006, 2007, and for 2008, activities to date and commitments for remainder of year.

Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V : Three calendar years before nomination and Each year thereafter through the present calendar year. (For 2008, activities to date and commitments for remainder of year.)

Non-Profit and Advocacy Organizations	Year(s)	Role
None

The two tables below represent Dr. Castellanos’ disclosure of significant interests and affiliations for: (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.

Dr. Castellanos has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.

KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options

6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify)

Disclosure of significant interests including: Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force

Commercial or Other Organization	Year(s)	Key #(s)
McNeil Consumer & Specialty Pharmaceuticals	2003-2005	3, 4
Janssen	2003	4

Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on the DSM-V Task Force, to the present. (For 2008, activities to date and commitments for remainder of year.)